Lycia’s $75M Raise Signals Big Bet on Novel Protein Degradation Tech

SOUTH SAN FRANCISCO, Calif. – June 25, 2026 – In a biotech funding landscape marked by discerning investors and a high bar for entry, Lycia Therapeutics has secured a significant vote of confidence. The clinical-stage company announced the completion of an oversubscribed $75 million Series D financing, a capital injection designed to propel its novel protein degradation platform into the next critical phase of human trials.

The financing was co-led by existing investor Janus Henderson Investors and new backer Balyasny Asset Management, and saw participation from a syndicate of prominent new and existing healthcare investors, including Adage Capital Management, OrbiMed, and Eli Lilly and Company. This influx of capital arrives as Lycia strengthens its C-suite, appointing a new Chief Financial Officer and promoting its General Counsel, signaling a clear strategy to build a durable enterprise ready for late-stage clinical and corporate challenges.

A Vote of Confidence in a Selective Market

Lycia's successful raise is more than just a financial milestone; it's a telling indicator of investor sentiment in the current market. After a challenging period for the biotech sector, 2024 has seen a cautious recovery, but capital is not flowing freely. Investors are concentrating larger bets on a smaller number of companies that possess a compelling trifecta: a differentiated scientific platform, a clear path through the clinic, and an experienced leadership team. Lycia appears to have checked all three boxes.

The $75 million figure is substantial, particularly for a company whose lead assets are now advancing toward early-stage clinical proof-of-concept. It underscores a belief in the potential of Lycia’s proprietary LYTAC (Lysosomal Targeting Chimera) platform to address diseases that have long eluded effective treatment. The oversubscribed nature of the round further amplifies this confidence, suggesting demand outstripped the shares on offer.

“With this financing and strengthened leadership team now in place, we believe we are well-positioned to execute on our clinical programs while advancing the next generation of cataLYTAC degraders,” said Aetna Wun Trombley, Ph.D., President and Chief Executive Officer of Lycia. She highlighted the company’s goal of demonstrating Phase 1 clinical proof-of-concept in patients, a pivotal step in de-risking the technology.

The quality of the investor syndicate speaks volumes. “By driving selective depletion of disease-causing proteins, we believe Lycia’s degraders could represent a potentially best-in-class option to transform the care of patients suffering from immune-mediated conditions,” noted Vish Sridharan, M.D., Assistant Portfolio Manager at Janus Henderson Investors. This perspective from a lead investor frames the financing not as a speculative venture, but as a strategic investment in a technology poised to redefine a standard of care.

A New Frontier in Protein Degradation

At the heart of Lycia's value proposition is a sophisticated scientific platform that opens a new front in the war on disease. The company is a pioneer in the field of targeted protein degradation, but with a crucial twist. While much of the industry has focused on PROTACs (Proteolysis Targeting Chimeras) that destroy problematic proteins inside the cell, Lycia’s LYTAC platform targets proteins that are outside the cell or embedded in the cell membrane.

This is a critical distinction. Many drivers of autoimmune and allergic diseases are extracellular proteins—such as rogue antibodies or signaling molecules—that have been difficult to drug with traditional small molecules or even biologics. Lycia's technology works by creating a molecular bridge. Its cataLYTAC™ degraders are designed to bind simultaneously to a disease-causing target protein and a specific receptor on the cell surface that triggers a natural cellular recycling process. This complex is then engulfed by the cell and shuttled to the lysosome—the cell's 'incinerator'—where the harmful protein is destroyed. The 'cataLYTAC' name signifies that these degraders are catalytic, meaning a single molecule can facilitate the destruction of many target proteins, potentially leading to a more profound and durable effect at lower doses.

The scientific pedigree of this approach is impeccable, as the company was established in collaboration with Nobel laureate Carolyn Bertozzi, Ph.D., a pioneer in chemistry and glycobiology. The newly raised funds will directly support the clinical advancement of Lycia’s two lead candidates, which exemplify the platform's potential.

First is LCA-0061, a degrader targeting Immunoglobulin E (IgE), the antibody central to allergic reactions. The goal is to treat food allergies and other allergic diseases by physically eliminating IgE from the body, rather than simply blocking its function. Second is LCA-0321, which is designed to selectively deplete the autoantibodies (TRAbs) that cause Graves' disease, an autoimmune condition that leads to hyperthyroidism. By removing the root cause of the autoimmune attack, Lycia hopes to offer a cure that avoids the destructive therapies used today.

Building the C-Suite for Clinical and Corporate Growth

Translating groundbreaking science into commercial success requires more than just capital; it requires seasoned leadership capable of navigating the complex path of clinical development, intellectual property protection, and corporate strategy. Lycia’s concurrent leadership appointments are a clear move to fortify this foundation.

The appointment of Amy Bachrodt as Chief Financial Officer is particularly noteworthy. Bachrodt brings over 18 years of finance leadership, most recently from Maze Therapeutics, where she was instrumental in raising over $1 billion and helped steer the company toward its 2025 initial public offering. This specific experience in taking a platform-based biotech public is an invaluable asset, strongly suggesting that Lycia is building the internal capabilities required for a potential IPO or other major strategic transaction in the coming years.

Simultaneously, the promotion of Karen Flick to General Counsel bolsters the company’s legal and strategic defenses. With nearly 25 years of experience, Flick’s expertise in intellectual property is paramount for a company whose core value lies in its proprietary LYTAC platform. In the hyper-competitive biotech space, a robust patent estate is the bedrock of long-term value, and Flick’s role will be to ensure Lycia’s innovations are rigorously protected as it moves toward the market and potential partnerships.

Together, these leadership moves signal that Lycia is thinking beyond the next clinical milestone. The company is assembling the financial and legal acumen necessary to scale, manage the immense costs of late-stage trials, and ultimately execute a successful corporate strategy, whether that involves going public, striking a major partnership, or navigating an acquisition. With capital in the bank, a novel scientific engine, and an experienced crew at the helm, Lycia is now positioned to focus on the most important task ahead: proving its technology can make a difference in patients.